The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Early results from EPCORE CLL-1 trial: subcutaneous epcoritamab in patients with Richter’s syndrome
Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, presents initial data from the ongoing Phase Ib/II EPCORE CLL-1 trial (NCT04623541) evaluating the efficacy of subcutaneous epcoritamab in patients with Richter’s transformation. Prof. Kater begins by highlighting that Richter’s syndrome is associated with poor outcomes in patients with hematological malignancies such as chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL). The EPCORE CLL-1 trial found that epcoritamab was able to induce high response rates in patients with LBCL. These findings are supported by a separate study (NCT03625037) in patients with non-Hodgkin lymphoma (NHL) reporting that some patients were able to achieve complete remission (CR). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Abbvie, Astra Zeneca, BMS, Janssen, Roche/Genentech: Research Funding; Janssen, LAVA: Patents & Royalties: Pending; Astra Zeneca, BMS, Roche/Gennetech, Janssen, Abbvie, LAVA: Membership on an entity’s Board of Directors or advisory committees; Abbvie, Astra Zeneca, Janssen: Other: Speakers fee; Amsterdam UMC, University of Amsterdam: Current Employment.
